

# 1 Convalescent plasma treatment of severe COVID-19: A matched control study

2 Sean T. H. Liu, M.D., Ph.D., Icahn School of Medicine at Mount Sinai

3 Hung-Mo Lin, Sc.D., Icahn School of Medicine at Mount Sinai

4 Ian Baine, M.D., Ph.D., Icahn School of Medicine at Mount Sinai

5 Ania Wajnberg, M.D., Icahn School of Medicine at Mount Sinai

6 Jeffrey P. Gumprecht, M.D., Icahn School of Medicine at Mount Sinai

7 Farah Rahman, D.O., Icahn School of Medicine at Mount Sinai

8 Denise Rodriguez, A.A.S., Icahn School of Medicine at Mount Sinai

9 Pranai Tandon, M.D., Icahn School of Medicine at Mount Sinai

10 Adel Bassily-Marcus, M.D., Icahn School of Medicine at Mount Sinai

11 Jeffrey Bander, M.D., Icahn School of Medicine at Mount Sinai

12 Charles Sanky, B.A., Icahn School of Medicine at Mount Sinai

13 Amy Dupper, M.A., M.P.H., Icahn School of Medicine at Mount Sinai

14 Allen Zheng, M.S., Icahn School of Medicine at Mount Sinai

15 Deena R. Altman, M.D., Icahn School of Medicine at Mount Sinai

16 Benjamin K. Chen, M.D., Ph.D., Icahn School of Medicine at Mount Sinai

17 Florian Krammer, Ph.D., Icahn School of Medicine at Mount Sinai

18 Damodara Rao Mendu, Ph.D., Icahn School of Medicine at Mount Sinai

19 Adolfo Firpo-Betancourt, M.D., Icahn School of Medicine at Mount Sinai

20 Matthew A. Levin, M.D., Icahn School of Medicine at Mount Sinai

21 Emilia Bagiella, Ph.D., Icahn School of Medicine at Mount Sinai

22 Arturo Casadevall, M.D., Ph.D., Johns Hopkins Bloomberg School of Public Health

23 Carlos Cordon-Cardo, M.D., Ph.D., Icahn School of Medicine at Mount Sinai

24 Jeffrey S. Jhang, M.D., Icahn School of Medicine at Mount Sinai

25 Suzanne A. Arinsburg, D.O., Icahn School of Medicine at Mount Sinai

26 David L. Reich, M.D., Icahn School of Medicine at Mount Sinai

27 Judith A. Aberg, M.D.\* , Icahn School of Medicine at Mount Sinai

28 Nicole M. Bouvier, M.D.\*† , Icahn School of Medicine at Mount Sinai

29  
30 \* Drs. Aberg and Bouvier contributed equally to this article. † Correspondence to [nicole.bouvier@mountsinai.org](mailto:nicole.bouvier@mountsinai.org).

31 **Abstract**

32 *Background*

33 Since December 2019, Coronavirus Disease 2019 (COVID-19) has become a global pandemic,  
34 causing mass morbidity and mortality. Prior studies in other respiratory infections suggest that  
35 convalescent plasma transfusion may offer benefit to some patients. Here, the outcomes of  
36 thirty-nine hospitalized patients with severe to life-threatening COVID-19 who received  
37 convalescent plasma transfusion were compared against a cohort of retrospectively matched  
38 controls.

39 *Methods*

40 Plasma recipients were selected based on supplemental oxygen needs at the time of enrollment  
41 and the time elapsed since the onset of symptoms. Recipients were transfused with convalescent  
42 plasma from donors with a SARS-CoV-2 (severe acute respiratory disease coronavirus 2) anti-  
43 spike antibody titer of  $\geq 1:320$  dilution. Matched control patients were retrospectively identified  
44 within the electronic health record database. Supplemental oxygen requirements and survival  
45 were compared between plasma recipients and controls.

46 *Results*

47 Convalescent plasma recipients were more likely than control patients to remain the same or  
48 have improvements in their supplemental oxygen requirements by post-transfusion day 14, with  
49 an odds ratio of 0.86 (95% CI: 0.75~0.98;  $p=0.028$ ). Plasma recipients also demonstrated  
50 improved survival, compared to control patients (log-rank test:  $p=0.039$ ). In a covariates-adjusted  
51 Cox model, convalescent plasma transfusion improved survival for non-intubated patients  
52 (hazard ratio 0.19 (95% CI: 0.05 ~0.72);  $p=0.015$ ), but not for intubated patients (1.24 (0.33~4.67);  
53  $p=0.752$ ).

54 *Conclusions*

55 Convalescent plasma transfusion is a potentially efficacious treatment option for patients  
56 hospitalized with COVID-19; however, these data suggest that non-intubated patients may  
57 benefit more than those requiring mechanical ventilation.

58

59 **Introduction**

60 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a positive-sense, single-  
61 stranded RNA virus belonging to the family *Coronaviridae*. Humans infected with SARS-CoV-2  
62 may develop Coronavirus Disease 2019 (COVID-19), which manifests across a wide spectrum of  
63 clinical severity ranging from a mild upper respiratory tract illness to a diffuse viral pneumonia  
64 causing acute respiratory failure, with sequelae including acute lung injury, multi-organ  
65 dysfunction syndrome, and death.<sup>1-3</sup> Antibody responses to coronavirus infections typically  
66 appear 2-3 weeks after the onset of illness and are rarely observed earlier.<sup>4-6</sup>

67 Although the relationship between disease severity and antibody response has yet to be firmly  
68 established,<sup>7</sup> transfusion with convalescent plasma may provide a therapeutic option in the  
69 current treatment-limited environment.<sup>8-10</sup> Historical evidence supports the efficacy of  
70 convalescent plasma transfusions to treat a variety of infectious diseases, including influenza,  
71 Junin virus, and severe acute respiratory syndrome (SARS).<sup>11-14</sup> Initial data supporting  
72 convalescent plasma transfusions for COVID-19 include three case series from China of 5, 10, and  
73 6 patients.<sup>15-17</sup> In respiratory infections specifically, the strongest evidence suggests that the  
74 benefit of passive antibody transfer is most demonstrable in patients who were treated within  
75 days of symptom onset.<sup>12,13,18,19</sup> Therefore, we hypothesized that treatment of patients with  
76 convalescent plasma early in the disease course may reduce morbidity and mortality associated

77 with COVID-19. Presented here are preliminary outcomes for 39 patients with severe to life-  
78 threatening COVID-19 who received convalescent plasma transfusions at a single academic  
79 medical center, The Mount Sinai Hospital, in New York City.

## 80 **Methods**

### 81 *Patients*

82 Forty-five adult patients were identified as eligible for COVID-19 convalescent plasma transfusion  
83 under the criteria established for the FDA single patient emergency investigational new drug  
84 (eIND) process. FDA authorization was requested and obtained for COVID-19 convalescent  
85 plasma transfusion. Four patients improved and 2 patients withdrew consent prior to receipt of  
86 plasma, leaving 39 evaluable patients who received COVID-19 convalescent plasma. Patients  
87 were hospitalized in a single academic medical center in New York City for COVID-19 between 24  
88 March 2020 and 8 April 2020. Patients were screened by symptom duration and by severity of  
89 disease on a case-by-case basis, as assessed by oxygen supplementation requirements and  
90 laboratory parameters. Patients or their legally authorized representatives provided informed  
91 consent prior to treatment. Both treatment and research were performed with the oversight of  
92 the Icahn School of Medicine at Mount Sinai Institutional Review Board (IRB).

### 93 *Convalescent plasma transfusion*

94 Convalescent plasma donors were screened for SARS-CoV-2 antibody titers by a two-step Spike  
95 protein-directed ELISA.<sup>20,21</sup> Donors with anti-spike antibody titers  $\geq 1:320$  were referred for blood  
96 collection at the New York Blood Center, which performed the plasmapheresis and then returned  
97 convalescent plasma units to The Mount Sinai Hospital. Plasma recipients were transfused with  
98 two units of ABO-type matched convalescent plasma. Each unit, approximately 250 milliliters in

99 volume, was infused over 1 to 2 hours. Recipients were monitored every 15 minutes for signs of  
100 transfusion-related reactions and then followed post-transfusion for outcomes.

### 101 *Statistical analysis*

102 To confirm the independent effect of convalescent plasma transfusion on improvement in  
103 oxygenation and survival, we conducted a propensity score-matched analysis using The Mount  
104 Sinai Hospital's COVID-19 confirmed patient pool from the same calendar period (24 March 2020  
105 to 8 April 2020). A logistic regression was fit to predict the potential for plasma therapy based  
106 on time series data obtained at baseline upon admission, prior to transfusion, and the day of  
107 transfusion. Among the predictors, exact matching was enforced on the administration of  
108 hydroxychloroquine and azithromycin, intubation status and duration, length of hospital stay,  
109 and oxygen requirement on the day of transfusion. Other medications were administered too  
110 infrequently to enforce exact matching. Balance was well achieved between the plasma and  
111 control groups, as all predictors had a standardized mean difference less than 0.2. Details of the  
112 matching method and results are described in the Supplementary Appendix. A medical data  
113 team reviewed charts of the control patients to determine outcomes at 1, 7, and 14 days. The  
114 data team was not informed of the recipient to whom each control patient was matched. Because  
115 control patients were matched to plasma recipients by length of stay prior to transfusion, "day  
116 0" was defined as the day of transfusion for the plasma recipients and as the corresponding day  
117 in the hospitalization course of the control patients.

### 118 *Oxygen supplementation*

119 Patients were then evaluated for their supplemental oxygen requirements and survival at three  
120 time points: days 1, 7, and 14 post-transfusion. Four categories of supplemental oxygen use  
121 status were collected for both cases and controls. These include, in order of increasing severity:

122 room air without supplemental oxygen required; low-flow oxygen delivery by standard nasal  
123 cannula; high-flow oxygen delivery, including non-rebreather mask; high-flow nasal cannula or  
124 bi-level positive airway pressure (BiPAP) non-invasive ventilation; and mechanical ventilation. A  
125 patient's oxygenation status at the three time points was considered to have worsened if they  
126 changed from a lower- to a higher-severity category compared to Day 0, or if they had died prior  
127 to the time point. A generalized estimating equations (GEE) approach with a logit link for binary  
128 data was used to model the effect of plasma on the odds of oxygenation improvement on days  
129 1, 7, and 14 following transfusion, controlling for oxygen status on day 0. An independent  
130 working correlation structure was assumed for the patients within each cluster; however, the p-  
131 values were calculated based on the empirical standard errors. Since some patients were  
132 discharged with continued oxygen supplementation, the oxygen status of discharged patients  
133 was assumed to be no worse than low-flow oxygen by standard nasal cannula.

#### 134 *Survival*

135 Kaplan-Meier survival curves and the log rank test were used to depict the overall post-  
136 transfusion survival. A Cox model was fit to estimate the hazard ratio for in-hospital mortality  
137 for the plasma group, with matched clusters treated as random effects and onset of intubation  
138 as a time-varying covariate. In addition, interactions between convalescent plasma  
139 administration and intubation duration were tested to see if the plasma effects were the same  
140 in subgroups.

141 Both oxygen status and survival models were adjusted for duration of symptoms prior to  
142 admission and drugs administered, as these data were only ascertained after the matching was  
143 completed. The initial drug list consisted of COVID-19 therapies used during the time of the

144 study that included azithromycin, broad-spectrum antibiotics, hydroxychloroquine, therapeutic  
145 anticoagulants, corticosteroids, directly acting antivirals, stem cells, and interleukin 1 and  
146 interleukin 6 inhibitors. Only those that had a p-value < 0.5, however, were included in the final  
147 model for adjustment. A liberal p-value was used here to be inclusive of any potential  
148 confounders. As a sensitivity analysis, the 1:2 matching without replacement data were also  
149 analyzed, where the balance between the matched pairs was enhanced but the study power  
150 was reduced. Descriptive data are reported as number (percent), mean ( $\pm$  standard deviation)  
151 or median [min, max], as appropriate. Analysis was performed using SAS 9.4 (SAS Institute Inc.,  
152 Cary, NC). All tests were 2-sided and statistical significance was defined as a p value < 0.05,  
153 unless otherwise indicated.

## 154 **Results**

### 155 *Recipient characteristics*

156 The average age of the recipients of convalescent plasma transfusion was 55 ( $\pm$  13) years (Table  
157 1). The cohort was approximately two-thirds male and one-third female, similar to the  
158 proportions of men and women with severe disease in prior studies.<sup>1</sup> Recipients generally had  
159 few baseline co-morbidities: 54% were obese (body mass index  $\geq$ 30) and 18% had a current or  
160 former history of tobacco use. One patient had end-stage renal disease requiring peritoneal  
161 dialysis. The median duration of symptoms prior to initial presentation was 7 [0, 14] days.  
162 Inflammatory markers were elevated with median d-dimer of 1.4 [0.27, >20]  $\mu$ g/mL fibrinogen  
163 equivalent units, median ferritin 1135 [107, 7441] ng/mL, and median C-reactive protein 159 [12,  
164 319] mg/L. The median time between admission and transfusion was 4 [1, 7] days. On the day of  
165 transfusion, the majority of the recipients were requiring supplemental oxygen via a non-invasive  
166 delivery device (87%). Four plasma recipients (10%) were mechanically ventilated at the time of

167 transfusion. In addition to receiving convalescent plasma transfusion, many recipients received  
168 a variety of inpatient pharmacotherapies throughout their hospitalizations (Table 2). There were  
169 no significant differences between plasma recipients and control patients in exposures to  
170 measured pharmacotherapies, except for therapeutic anticoagulation.

### 171 *Respiratory Status*

172 Plasma recipients and control patients were 100% matched on their supplemental oxygen  
173 requirement on day 0. Of them, 69.2% were receiving high-flow oxygen and 10.3% were receiving  
174 invasive mechanical ventilation. By day 14, clinical condition had worsened in 18.0% of the  
175 plasma patients and 24.3% in the control patients ( $p=0.167$ , Cochran-Mantel-Haenszel test). The  
176 covariates-adjusted odds ratio for worsening oxygenation on day 14 was 0.86 (95% CI: 0.75~0.98;  
177  $p=0.028$ ) (Figure 1). The effect of plasma appeared to be confounded by the use of therapeutic  
178 anticoagulants (unadjusted vs. adjusted OR: 0.90 vs. 0.84), but not on other types of drugs or  
179 duration of symptoms before admission (OR remained in the range of 0.90~0.91). On days 1 and  
180 7, the plasma group also showed a reduction in the proportion of patients with worsened  
181 oxygenation status, but the group difference did not reach statistical significance.

### 182 *Survival*

183 As of 1 May 2020, 12.8% of plasma recipients and 24.4% of the 1:4 matched control patients had  
184 died (21.6% in the 1:2 matched dataset), and 71.8% and 66.7% (68.9%) had been discharged alive,  
185 respectively. The median follow-up time was 11 [1, 28] days for the plasma group and 9 [0, 31]  
186 days for the control group. Overall, we observed improved survival for the plasma group (log-  
187 rank test:  $p=0.039$ ) (Figure 2). In a covariates-adjusted Cox model, convalescent plasma  
188 transfusion was significantly associated with improved survival in non-intubated patients (hazard  
189 ratios: 0.19 (95% CI: 0.05 ~0.72);  $p=0.015$ ), but not in intubated patients (1.24 (0.33~4.67);

190 p=0.752) (P-value for the plasma and intubation interaction term was 0.050). There is no  
191 evidence that the effect of plasma depended on the duration of symptoms ( $p=0.19$  for the plasma  
192 by duration interaction). The results remain robust in the model without covariates adjustment  
193 and in the 1:2 matched sample (Figure 3).

## 194 **Discussion**

195 The COVID-19 pandemic poses an unprecedented challenge, as physicians and scientists struggle  
196 in real time to identify effective interventions against SARS-CoV-2 and its complications. This  
197 initial assessment offers evidence in support of convalescent plasma transfusion as an effective  
198 intervention in COVID-19. Preliminary data suggest a potential mortality benefit, but greater  
199 numbers are needed to draw definitive conclusions. Interestingly, these data suggest that the  
200 survival effect of convalescent plasma may begin to manifest more than 1 week after transfusion.  
201 If this observation is borne out in subsequent studies, it could indicate that convalescent plasma  
202 prevents longer-term complications, such as acute lung injury or multi-organ dysfunction  
203 syndrome; however, this speculation awaits confirmation in a larger patient cohort.

204 This study has many unique strengths. It describes the largest cohort of COVID-19 patients  
205 treated with convalescent plasma thus far worldwide. Furthermore, New York City has a large  
206 and very diverse population, and its metropolitan area was among the earliest and hardest hit by  
207 the COVID-19 pandemic in the United States. Over this study's 16-day enrollment period (24  
208 March 2020 to 8 April 2020), the Mount Sinai Health System admitted 4,152 confirmed COVID-  
209 19-positive patients. This large pool from which to draw control patients permitted an aggressive  
210 matching algorithm. Data from three different time frames -- baseline, prior to transfusion, and  
211 day of transfusion -- informed the matching of controls to cases to maximize their similarity.

212 In addition, the efficacy of passive antibody transfer relies heavily on the quality of the donor  
213 convalescent plasma. Mount Sinai rapidly developed and clinically deployed an ELISA to titrate  
214 SARS-CoV-2-specific antibodies in serum,<sup>18</sup> enabling our center to refer for blood collection only  
215 those convalescent donors with the highest peripheral serum antibody titers of  $\geq 1:320$ .<sup>22</sup> Prior  
216 smaller studies have reported on a variety of titer cutoffs,<sup>15,16</sup> and at the time of this publication  
217 some centers are bypassing donor antibody titer pre-collection completely.<sup>17</sup> Although the total  
218 quantity of anti-SARS-CoV-2 spike antibodies were assessed, it must be noted that we have not  
219 yet assessed the functionality of these antibodies in neutralizing the virus. Recent studies with  
220 SARS CoV-2 have generally found a high correlation between ELISA S protein binding activity and  
221 neutralization of SARS CoV-2.<sup>21,23</sup>

222 Although controls were retrospectively identified by propensity matching, the conclusions drawn  
223 from these data are not as robust as a prospective, randomized, placebo-controlled study.  
224 Furthermore, the convalescent plasma recipient cohort is highly heterogeneous in regards to  
225 oxygen needs at the time of transfusion and the duration of symptoms prior to admission. Other  
226 than intubated versus non-intubated patients, the small size of this cohort lacks sufficient power  
227 to permit additional subgroup analyses. We did not observe significant benefit of convalescent  
228 plasma in intubated patients, consistent with past literature demonstrating that passive antibody  
229 transfer therapies are most efficacious early in disease.<sup>12,13,18,19</sup> However, the number of  
230 intubated patients in this study is small, limiting our ability to reach any conclusions about this  
231 population. Future studies that include more mechanically ventilated patients will be needed to  
232 address this uncertainty.

233 No significant transfusion-related morbidity or mortality were observed in the convalescent  
234 plasma recipient cohort; however, potential harms are associated with plasma transfusion. There

235 is a risk of fluid volume overload, particularly in patients with end-stage renal disease or advanced  
236 heart failure. Allergic reactions to plasma are typically mild and self-limited. Plasma naturally  
237 contains procoagulants, whose additive effects are unknown in this disease, which is  
238 independently associated with hypercoagulability;<sup>24</sup> thus, pending more data, additional caution  
239 should be exercised in patients with acute thrombotic events. Convalescent plasma transfusions  
240 also have theoretical risks, such as hindering the maturation of the patient's own adaptive  
241 immune memory response and antibody-dependent enhancement. While keeping these risks in  
242 mind, additional studies are needed to confirm these findings and draw more definitive  
243 conclusions about the efficacy of convalescent plasma transfusion for the treatment of COVID-  
244 19 in different populations.

245

---

## 246 **Acknowledgements**

247 We thank all of the patients who participated in this study and their families. We also  
248 acknowledge the generosity of the thousands of anonymous tri-state area residents who  
249 recovered from COVID-19 and then volunteered to donate convalescent plasma for the benefit  
250 of others. We thank the New York Blood Center, Liise-anne Pirofski, Thomas Schneider, Carina  
251 Seah, Sindhu Srinivas, Douglas Tremblay, Freddy Nguyen, Miwa Geiger, Chaim Lebovits, and  
252 Jacqueline Lustgarten. We acknowledge the assistance of Icahn School of Medicine at Mount  
253 Sinai medical students: Sofia Ahsanuddin, Arence Paasewe, Ranjan Upadhyay, George  
254 Mellgard, Tyler Martinson, Bhavana Patil, Cynthia Luo, Saloni Agrawal, Alina Siddiqui, Julia  
255 Schwarz, Lydia Piendel, Jacqueline Emerson, Harrison Kaplan, Emma Klein, Mariely Garcia,  
256 James Johnson, Luke Maillie, and Elena Baldwin. We also appreciate the clinical expertise of  
257 the Mount Sinai Convalescent Plasma Squad: Nicholas Shuman, Daniela Delbeau, Donna

258 Catamero, Gillian Sanchez, Suzan Aird, Manpreet Mann, Tarashon Broome, Sonia Kleiner-Arje,  
259 Louise Wolf, Angela Lee, Lisa Gaynes, and Karyn Goodman. We dedicate this work to the New  
260 Yorkers who have lost their lives to COVID-19 with a special dedication to the health care  
261 workers who will always be remembered for their selflessness during this pandemic.

## 262 **Author Affiliations**

263 From the Division of Infectious Diseases (S.T.H.L., J.P.G., F.R., A.D., D.R.A., B.K.C., J.A.A., N.M.B.),  
264 and the Department of Population Health Science and Policy (H.-M.L., E.B.), and the  
265 Department of Pathology, Molecular and Cell-Based Medicine (I.B., D.R.M., A.F.B., C.C.-C., J.S.J.,  
266 S.A.A.), and the Department of Medicine (A.W., J.B.), and The Tisch Cancer Institute (D.R.), and  
267 the Department of Surgical Critical Care (A.B.-M.), and the Department of Pulmonary and  
268 Critical Care Medicine (P.T.), and the Department of Anesthesiology, Perioperative and Pain  
269 Medicine (M.A.L., D.L.R.), and the Department of Medical Education (C.S.), and the Department  
270 of Microbiology (S.T.H.L., A.Z., F.K., N.M.B) – all at the Icahn School of Medicine at Mount Sinai;  
271 and the Department of Molecular Microbiology & Immunology, John Hopkins School of  
272 Medicine (A.C.).

## 273 **Disclosures**

274 Dr. Krammer reports that patent applications have been filed for the assay used to select  
275 plasma donors, and Mount Sinai has licensed its use to several companies. Dr. Aberg reports  
276 grants and personal fees from Gilead, grants and personal fees from Merck, grants and personal  
277 fees from Janssen, personal fees from Theratech, personal fees from Medicure, grants from  
278 Regeneron, grants and personal fees from Viiv, outside the submitted work. All other authors  
279 have nothing to disclose.

## 280 **References**

- 281 1. Richardson S, Hirsch JS, Narasimhan M, et al. Presenting Characteristics, Comorbidities, and  
282 Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA 2020.  
283 Published online ahead of print, doi:10.1001/jama.2020.6775.
- 284 2. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease  
285 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for  
286 Disease Control and Prevention. JAMA 2020;323:1239-1242.
- 287 3. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with  
288 COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395:1054-62.
- 289 4. Callow KA, Parry HF, Sergeant M, Tyrrell DA. The time course of the immune response to  
290 experimental coronavirus infection of man. Epidemiol Infect 1990;105:435-46.
- 291 5. Ko JH, Muller MA, Seok H, et al. Serologic responses of 42 MERS-coronavirus-infected patients  
292 according to the disease severity. Diagn Microbiol Infect Dis 2017;89:106-11.
- 293 6. Hsueh PR, Huang LM, Chen PJ, Kao CL, Yang PC. Chronological evolution of IgM, IgA, IgG and  
294 neutralisation antibodies after infection with SARS-associated coronavirus. Clin Microbiol Infect  
295 2004;10:1062-6.
- 296 7. Zhao J, Yuan Q, Wang H, et al. Antibody responses to SARS-CoV-2 in patients of novel  
297 coronavirus disease 2019. Clin Infect Dis 2020. Published online ahead of print,  
298 <https://doi.org/10.1093/cid/ciaa344>.
- 299 8. Casadevall A, Pirofski LA. The convalescent sera option for containing COVID-19. J Clin Invest  
300 2020;130:1545-8.
- 301 9. Chen L, Xiong J, Bao L, Shi Y. Convalescent plasma as a potential therapy for COVID-19. Lancet  
302 Infect Dis 2020;20:398-400.
- 303 10. Roback JD, Guarner J. Convalescent Plasma to Treat COVID-19: Possibilities and Challenges.  
304 JAMA 2020;323:1561-1562.

- 305 11. Luke TC, Kilbane EM, Jackson JL, Hoffman SL. Meta-analysis: convalescent blood products for  
306 Spanish influenza pneumonia: a future H5N1 treatment? *Ann Intern Med* 2006;145:599-609.
- 307 12. Mair-Jenkins J, Saavedra-Campos M, Baillie JK, et al. The effectiveness of convalescent plasma  
308 and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral  
309 etiology: a systematic review and exploratory meta-analysis. *J Infect Dis* 2015;211:80-90.
- 310 13. Hung IFN, To KKW, Lee CK, et al. Hyperimmune IV immunoglobulin treatment: a multicenter  
311 double-blind randomized controlled trial for patients with severe 2009 influenza A(H1N1) infection.  
312 *Chest* 2013;144:464-73.
- 313 14. Enria DA, Briggiler AM, Fernandez NJ, Levis SC, Maiztegui JI. Importance of dose of neutralising  
314 antibodies in treatment of Argentine haemorrhagic fever with immune plasma. *Lancet* 1984;2:255-6.
- 315 15. Shen C, Wang Z, Zhao F, et al. Treatment of 5 Critically Ill Patients With COVID-19 With  
316 Convalescent Plasma. *JAMA* 2020;323:1582-1589.
- 317 16. Duan K, Liu B, Li C, et al. Effectiveness of convalescent plasma therapy in severe COVID-19  
318 patients. *Proc Natl Acad Sci U S A* 2020;117:9490-6.
- 319 17. Ye M, Fu D, Ren Y, et al. Treatment with convalescent plasma for COVID-19 patients in Wuhan,  
320 China. *J Med Virol* 2020. Published online ahead of print, <https://doi.org/10.1002/jmv.25882>.
- 321 18. Finland M. The serum treatment of lobar pneumonia. *New Engl J Med* 1930;202:1244-7.
- 322 19. Cecil RL. Remarks on THE SERUM TREATMENT OF PNEUMONIA. *Br Med J* 1932;2:657-62.
- 323 20. Stadlbauer D, Amanat F, Chromikova V, et al. SARS-CoV-2 Seroconversion in Humans: A Detailed  
324 Protocol for a Serological Assay, Antigen Production, and Test Setup. *Curr Protoc Microbiol*  
325 2020;57:e100.
- 326 21. Amanat F, Stadlbauer D, Strohmeier S, et al. A serological assay to detect SARS-CoV-2  
327 seroconversion in humans. *medRxiv* 2020; <https://doi.org/10.1101/2020.03.17.20037713>.
- 328 22. An EU programme of COVID-19 convalescent plasma collection and transfusion: Guidance on  
329 collection, testing, processing, storage, distribution and monitored use. Brussels: European Commission

- 330 Directorate-General for Health and Food Safety, April 4 2020.  
331 ([https://ec.europa.eu/health/sites/health/files/blood\\_tissues\\_organs/docs/guidance\\_plasma\\_covid19\\_](https://ec.europa.eu/health/sites/health/files/blood_tissues_organs/docs/guidance_plasma_covid19_en.pdf)  
332 [en.pdf](https://ec.europa.eu/health/sites/health/files/blood_tissues_organs/docs/guidance_plasma_covid19_en.pdf).)
- 333 23. Okba NMA, Muller MA, Li W, et al. SARS-CoV-2 specific antibody responses in COVID-19  
334 patients. medRxiv 2020; <https://doi.org/10.1101/2020.03.18.20038059>.
- 335 24. Llitjos JF, Leclerc M, Chochois C, et al. High incidence of venous thromboembolic events in  
336 anticoagulated severe COVID-19 patients. J Thromb Haemost 2020. Published online ahead of print,  
337 <https://doi.org/10.1111/jth.14869>.
- 338

339 **Table 1. Demographics and clinical parameters of recipients prior to transfusion**

Characteristic*	Patients (N = 39)
<b>Demographics</b>	
Mean age ± SD – year	55 ± 13
Sex –	
Male / Female	25 (64) / 14 (36)
Mean Body-mass index ± SD †	31.7 ± 6.0
Coexisting disorder – no. (%)	
Asthma	3 (8)
Cancer¶	2 (5)
Chronic kidney disease	1 (3)
Chronic obstructive pulmonary disease	1 (3)
Current or former smoker	7 (18)
Diabetes mellitus	8 (21)
Hemorrhagic or ischemic stroke	0
Human immunodeficiency virus	0
Obesity	21(54)
Obstructive sleep apnea	2 (5)
Median duration of symptoms before admission – days	7 [0, 14]
Presenting symptoms – no. (%)	
Fever	26 (67)
Shortness of breath	26 (67)
Cough	24 (62)
Diarrhea	8 (21)
Sputum production	3 (8)

Sore throat	2 (5)
Vital signs on admission – no. (%)	
Temperature >100.4°F or 38°C	13 (33)
Heart rate >100 beats per min	22 (56)
Respiratory rate ≥ 20 breaths per min	28 (72)
Imaging – no. (%)	
Chest radiography	38 (97)
Chest computed tomography	3 (8)
<b>Clinical parameters</b>	
Laboratory data prior to transfusion	
White-cell count	
Median [range] – per mm <sup>3</sup>	7600 [3900-22600]
Distribution – no (%)	
≥10,000/mm <sup>3</sup>	10 (26)
≤4000/mm <sup>3</sup>	2 (5)
Aspartate aminotransferase >40 U/liter – no (%)	26 (67)
Alanine aminotransferase >40/liter – no (%)	18 (46)
Lactate ≥1.5 mmol/liter – no (%)	23 (59)
D-dimer, median [range] - µg/ml Fibrinogen Equivalent units	1.4 [0.27, >20]
Fibrinogen, mean (±S.D.) –no./total no. (mg/dl)	684±140
Ferritin, median [range] – ng/ml	1135 [107, 7441]
C-Reactive Protein, median [range] – mg/liter	159 [12, 319]

Interleukin-6, mean ( $\pm$ S.D.) – no./total no. (pg/ml)	178 $\pm$ 348
Length of stay prior to transfusion	
Median duration [range] – days	4 [1, 7]
Supplemental oxygen requirement prior to initiation of transfusion	
Standard nasal cannula – no. (%)	7 (18)
2 liters – no. (%)	0
3 liters – no. (%)	2 (5)
4 liters – no. (%)	2 (5)
$\geq$ 5 liters – no. (%)	3 (8)
High-flow oxygen, high-flow nasal cannula or BiPAP – no. (%)	27 (69)
Mechanical ventilation – no. (%)	4 (10)

---

340 \*Plus-minus values are mean  $\pm$ SD. Percentages may not total 100 because of rounding.

341 †The body-mass index is the weight in kilograms divided by the square of the height in meters.

342 ¶Cancer represents a patient with thyroid cancer status post resection and a patient with Gleason 6 prostate cancer.

343 ¶High-flow oxygen included venti-mask and non-rebreather mask; BiPAP = bi-level positive airway pressure.

344 \*Plus-minus values are mean  $\pm$ SD. Percentages may not total 100 because of rounding.

345 **Table 2. Recipient pharmacologic interventions**

		<b>1:4 matching</b>	<b>1:2 matching</b>
	<b>Patients</b>	<b>Controls</b>	<b>Controls</b>
<b>Pharmacologic interventions</b>	<b>(N = 39)</b>	<b>(N=156)</b>	<b>(N=74)</b>
<hr/>			
Antimicrobial agents – no. (%)			
Azithromycin	31 (79)	133 (85)	63 (85)
Broad spectrum antibiotics	29 (74)	112 (72)	57 (77)
Hydroxychloroquine	36 (92)	148 (95)	69 (93)
Investigational antivirals	1 (3)	9 (6)	4 (5)
Therapeutic anticoagulation – no. (%)	26 (67)	64 (41)	32 (43)
Anti-inflammatory agents – no. (%)			
Corticosteroids	22(56)	90 (58)	38 (51)
Interleukin-1 inhibitors	0	0	0
Interleukin-6 inhibitors	3 (8)	13 (8)	6 (8)


\* No significant differences were found between groups in both matched samples (p-values all >0.44), except for use of therapeutic anticoagulation (p <0.001 1:4 ratio and p=0.02 1:2 ratio).

346

347 **Figure 1. Comparison of oxygen requirements between Day 14 versus Day 0.**


348

349




\* Covariates adjusted. No significant differences were observed at day 1 (p=0.444) or day 7 (p=0.425).

350 **Figure 2. Survival Probability**



351

352 **Figure 3. Hazard ratios for in-hospital mortality**



\* Adjustment: Duration of symptoms prior to admission, therapeutic anticoagulant, broad spectrum antibiotics, and antivirals.

353